Therapeutic value of oncology products with a conditional approval from Health Canada: a cross-sectional study

Few new oncology drugs approved through the NOC/c pathway offer major therapeutic improvements over existing drugs.

Authors

Institutions

Publication Details

Journal
JRSM Open
Published
2025-03-01
DOI
https://doi.org/10.1177/20542704251325314
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Therapeutic value of oncology products with a conditional approval from Health Canada: a cross-sectional study

Joel Lexchin
1 links
JRSM Open
Health Systems, Economic Evaluations, Quality of Life
article

Therapeutic value of oncology products with a conditional approval from Health Canada: a cross-sectional study

Joel Lexchin
article en

Abstract

Few new oncology drugs approved through the NOC/c pathway offer major therapeutic improvements over existing drugs.

JRSM OpenVol. 16(3)
University of Toronto (CA), York University (CA)
Openalex Percentile: Top 92%
Health Systems, Economic Evaluations, Quality of Life
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Therapeutic value of oncology products with a conditional approval from Health Canada: a cross-sectional study — Joel Lexchin · JRSM Open (2025) | TGRS Research Map | TGRS